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Background
Many genetic factors play a major role in the outcome of unrelated donors (UD) hematopoietic stem cell transplantation (HSCT). Transforming growth factor b1 (TGF-β1) is a member of a highly pleiotrophic family of growth factors involved in the regulation of numerous immunomodulatory processes.
Design and Methods
We investigated the impact of TGFB1 single nucleotide polymorphisms (SNPs) at codons 10 and 25 on outcomes in 427 myeloablative-conditioned transplant patients. In addition, TGF-β1 plasma levels were measured in 263 patients and 327 donors.
Results
Patients homozygous for the SNP at codon 10 had increased non-relapse mortality (NRM) (3 years 46.8% vs. 29.4%, p=0.014) and reduced overall survival (OS) (5 years 29.3% vs. 42.2%, p=0.013), which remained significant in multivariate analysis for NRM (Hazard ratio (HR): 1.9; 95% confidence interval (CI) 1.23-2.96, p=0.004) and OS (HR: 1.5, 95% CI 1.00-2.28, p=0.048). There was no impact of donor genotype alone, although multiple SNPs within the pair were significantly associated with higher NRM (3 years 44% vs. 29%, p=0.021) and decreased OS (5 years 33.8% vs. 41.9%, p=0.033). In the 10/10 HLA matched transplants (n=280), non-wild type (wt) donors showed a trend to increase the incidence of acute graft-versus-host disease (aGvHD) II-IV (p=0.052). In multivariate analysis, when analyzed with patient genotype, non-wt pairs increased the incidence of overall aGvHD (Odds Ratio (OR): 2.2, 95% CI 1.11-4.7; p=0.025) and aGvHD II-IV (OR: 15.1, 95% CI 1.96-117.4; p=0.009).
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) using volunteer unrelated donors (UDs) is a lifesaving intervention for patients with hematological malignancies and a therapeutic approach when an HLAidentical sibling donor is not available. 1 The outcome has improved significantly over the last decade. This is due, in part, to the improved understanding of HLA matching and refinement in the resolution of tissue-typing techniques, which has lead to better donor selection;
2 and due to the increased safety in the procedure by changes in the conditioning regimens 3 and immunosupression, and better supportive care.
It is well recognized that numerous genetic factors in both patient and donor play a significant role in outcome. Apart from the well-defined HLA class I (HLA-A, -B and -C) and class II (HLA-DR, -DQ and -DP) genes, 4 several non-HLA genes have also been associated with variation in outcome.
5
Transforming growth factor β1 (TGF-β1) is a member of a highly pleiotrophic family of growth factors that are involved in the regulation of numerous immunomodulatory processes. The main source of TGF-β1 are T cells and platelets, although it can be secreted by additional cell types including epithelial, endothelial and connective tissue cells. 6 It's profibrotic properties have been well defined. 7 Studies have shown that TGF-β1 can inhibit effectors T cell proliferation and activation, decreases Th1 and Th2 cells differentiation, while promoting differentiation in Th17 cells.
8,9
Moreover, TGF-β1 is essential for the proliferation of induced Treg (iTreg) cells, 10,11 up regulation of FOXP3
12
and plays a role in the immunosuppressive function of Tregs due to cytokine secretion or membrane bound expression.
9,11,13
Several functional polymorphisms in the TGFB1 gene have been identified, such as a single nucleotide polymorphism (SNP) at codon 10 (coding(c).29T>C, protein(p).L10P) and at codon 25 (c.75G>C, p.A74P) of exon 1. Both polymorphisms are part of the signal sequence peptide 10, [14] [15] [16] and hence could cause alterations in cytokine secretion. While codon 25 SNPs have been consistently associated with decreased plasma levels, 17, 18 conflicting data have been published regarding the impact of codon 10 SNPs on plasma levels. [17] [18] [19] [20] [21] [22] These polymorphisms have been associated with an increased incidence of breast and colorectal neoplasia 20, 23 and worse outcome following solid organ transplantation 24 and sibling HSCT.
5,25,26
To date there is no published evidence of the possible role of these SNPs in UD HSCT, or of the TGF-β1 plasma levels and clinical outcomes following transplantation. Given the pathways in which TGF-β1 is involved, we hypothesized that these polymorphisms may influence the outcome of UD HSCT by modulating the immune response through a modification in the secretion processes of the cytokine.
Design and Methods

Patients characteristics
We genotyped, for the presence of a SNP at codons 10 and 25, a cohort of 427 patient/donor pairs who had undergone an UD HSCT using a donor provided by the Anthony Nolan Trust, in a UK transplant centre. All transplant pairs had high resolution HLA typing for six HLA genes (HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 
Ethical approval
All research samples and data were collected according to institutional review board-approved guidelines and protocols of each participating institution. Written informed consent was obtained from all recipients and donors.
Genotyping methods
Genomic DNA was extracted from whole blood using the salting out technique. 27 The genotyping was carried out using a Polymerase Chain Reaction (PCR) using Sequence-Specific-Primer (SSP). We used primers described by Perrey et al. 28 The internal control product for the PCR was human growth hormone described by Perrey et al. We used reagents provided by Bioline Ltd, London, UK. The PCR reaction was in a final volume of 12.5 mL, containing 0.5 mL of genomic DNA (100-200 ng/mL), 0.25 mL of each primer (25 mm), 1.25 mL of NH4 buffer (10x), 0.25-0.35 mL of MgCl2 (50 mM) depending on the reaction, 0.2 ml of dNTPs (12.5 mM each), 0.25 ml of internal control primers, 0.1 ml of DNA polymerase (5 U/mL) and 9.1-9.2 ml of s.H2O (depending on the reaction). The thermocycler procedure consisted of initial denaturation at 95°C for 2 minutes, follow by 37 cycles of 95°C for 30 seconds and different annealing temperature depending on the reaction (for codon 10T and 25G 65.5°C, for codon 10C 63.6°C and for codon 25C 61.1°C) for 40 seconds, followed by a final extension of 72°C for 30 seconds and +4∞C for 4 minutes.The products were analyzed by a 1.5% agarose gel electrophoresis and visualized by ethidium bromide staining. The target bands size was 233bp for codon 25, 241bp for codon 10, and the internal control was 429bp.
DNA sequencing of the polymorphic region of TGFB1 exon 1
In order to confirm the accuracy of the genotyping data from the SSP, we sequenced part of exon 1 that includes codons 10 and 25 in a proportion of samples. We used the following primers: sense 5´-GTAAAAC-GACGGCCAGTTCCGTGGGATACTGAGACAC and antisense 5´-CAGGAAACAGCTATGAC-CCAGTTTCTTCTGCCAGTCA. The sequences of which were tagged with M13 tails (M13 forward 5´-GTAAAACGACGGCCAGT and M13 reverse 5´-CAGGAAACAGCTATGAC. All results correlated with the SSP findings.
Luminex assay
The active form of TGF-β1 was measured by luminex (Panomincs, Inc., Fremont, CA, USA). Samples were obtained prior to the transplant. Plasma from patients and donors was extracted from whole blood after 5 minutes centrifugation at 1600rpm. Samples were stored at minus 70∞C. After thawing, the samples were spun at 1300rpm for 7 minutes at +4∞C; the supernatant was filtered through a filter plate with 0.45 mm pores (Millpore Corporation, MA, USA) at 1400rpm for 5 minutes. For the activation process, to 40 ml of the processed sample we added 10 ml of 1N HCl and after an incubation period of 10 minutes at room temperature we added 8 ml 1.2N OHNa/0.5M Hepes. The luminex assay was run according to the manufacture procedure. For each batch we ran a standard curve and two blank samples.
Statistical analysis
Statistical analysis was performed using SPSS version 11.0.4 (SPSS Inc, Chicago, IL, USA), R version 2.6.2 (http://r-project.org) and Prism version 5.0a (GraphPad Software, Inc., CA 92037, USA). In univariate analysis, the Overall Survival (OS) and Disease-Free Survival (DFS) probabilities were compared using log-rank statistic and calculated using a Kaplan-Meier method. For Relapse, Non Relapse Mortality (NRM) and chronic Graft-versus-Host Disease (cGvHD) we used Gray's test and analyzed these outcomes using the cumulative incidence (C.I.) method. The competing event for NRM was relapse, for relapse was death without relapse and for cGvHD was death and/or relapse without cGvHD. For acute Graft-versus-Host Disease (aGvHD), engraftment and cause of mortality we used the Chi Square statistic. For plasma level means comparison we used non-parametric tests (Kruskal-Wallis test for three groups comparison and Mann-Whitney test for two groups comparison). For multivariate analysis we use the Cox regression model for survival factors analysis and the Logistic regression for the aGvHD analysis. We included all factors that were significant in the univariate analysis with a p value of ≤0.2. For all the analysis the p value was two sided, and outcomes were consid- ered to be significant with a p value of >0.05, while a trend was considered with a p value of 0.05-0.1.
Results
Patients' codon 10 genotype observed frequencies were TC 52%, TT 37.2% and CC 10.8%, and in the donor were 49.4%, 38.2% and 12.4% respectively. For codon 25 genotype, the frequencies in the patients were GG 86.7%, GC 12.6% and CC 0.7% and in the donor were 84.1%, 15.5% and 0.5% respectively. These frequencies were similar to those previously described.
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Survival analysis
The Overall Survival (OS) and Non Relapse Mortality (NRM) in the entire cohort at five years were 40.9% and 41% respectively. The main causes of death were infection (21.8%), relapse (21.3%) and GvHD (4.9%).
Patient codon 10 genotype had a significant impact on survival outcomes. Patients homozygous for the SNP at TGFB1 codon 10 (CC) vs. others (TT-TC) had worse OS ( Figure 1A ) (2 and 5 years 31.8% and 29.3% vs. 48.7% and 42.2%, log-rank p=0.013) and higher NRM ( Figure  1B) (Table  2A) . Similarly, we performed a multivariate analysis for NRM, including in the analysis: patient and donor age, patient CMV status, T cell depletion, HLA mismatched and patient codon 10 genotype; we found that patient with the CC genotype had a significant increase in NRM (HR: 1.91; 95% CI, 1.23 to 2.96; p=0.004) ( Table  2B) .
We found no statistically significant differences due to the donor codon 10 genotype alone, however when we analyzed the impact of the total number of SNPs present in the pair, we found that multiple SNPs (in both patient and donor) (3-4 SNPs vs. 2 or less) were associated with a significantly decreased OS (2 and 5 years 33.8% and 33.8% vs. 48.9% and 41.9%, log-rank p=0.033) ( Figure 1E ) and a higher NRM (1 and 3 years 42% and 44% vs. 26% and 29%, respectively, Gray's test p=0.021) ( Figure 1F ).
When we analyzed the different causes of mortality, we found that the presence of the SNP at codon 10 in 
others (TT-TC) had worse OS (A) and higher NRM (B). There is a suggestion of dosage effect of the SNP in OS (C) and in NRM (D). The presence of 3 or 4 SNPs within the pair (PD.3-4 SNPs) is associated with significant reduction in OS (E) and increase in NRM (F).
the patient significantly impacted on the outcome. Patients homozygous for the SNP had a statistically significant higher probability of dying because of an infection compared to the other genotypes (CC 34.8% vs. TC/TT 20.3%, p=0.024).
Acute graft-versus-host disease
Acute GvHD was graded as none (grade 0), clinically significant (grade II-IV) and severe (grade III-IV). The overall incidence of aGvHD was 50.4%, aGvHD II-IV 27.4% and aGvHD III-IV 6.8%.
Regarding the association of TGFB1 codon 10 genotype and aGvHD, non-wt pairs (the presence of a SNP in the patient and/or the donor) had significantly more aGvHD II-IV (31% vs. 19%, p=0.031). HLA mismatches where also associated with a significant increase in GvHD (data not shown). In order to exclude the confounding effect of an HLA mismatch, we analyzed only the 10/10 HLA matched transplants (n=280). We found that the non-wt donor had trend to increase in aGvHD II-IV (29.9% vs. 20%, p=0.052). As in the survival analysis, there appears to be an additive effect between patients and donors genotype. The non-wt pairs had a significant increase in the incidence of overall aGvHD (51% vs. 32, p=0.018), aGvHD II-IV (30% vs. 2.5%, p<0.001) and a trend to an increase in the incidence of severe aGvHD (grade III-IV) (6.7% vs. 0%, p=0.077) compared to wt pairs (table 3). In the multivariate analysis, the non-wt pairs had a significant increase in overall aGvHD (HR: 2.1; 95% CI 1.06-4.4; p=0.025) (adjusted to patient age, source of transplant and DPB1 incompatibility) and aGvHD II-IV (HR: 15.1; 95% CI 1.96-117.4; p=0.009) ( Table 4) .
There was no significant impact of the codon 10 genotype on relapse, DFS, cGvHD and engraftment. No significant effect of codon 25 genotype on any transplant outcome was found.
Impact of codon 10 polymorphism on plasma level measurements
Due to the previously described association of codon 10 with the secretion process, we analyzed the possible association of the presence of the SNP and the plasma levels of the cytokine. We analyzed TGF-β1 plasma levels of 263 patients prior to the transplant. In contrast with previous data, we found no statistically significant difference in the plasma levels depending on codon 10 genotype (median CC 697.5, TC 730.0 and TT 537.1, p=0.24) (Figure 2 ). We also measured plasma levels on 327 healthy donors, with no significant result (median CC 737.1, TC 674.1 and TT 765.3, p=0.50) (data not shown). We then analyzed the possible impact of patient-donor pair plasma level and clinical outcomes. From a total of 234 pairs we found no significant effect of plasma levels on any clinical outcome. 
Discussion
A better understanding of the factors that are important in the biology of HSCT will help us to improve the outcome and give the patients a longer and better quality of life. We have shown in a large number of UD HSCT pairs that increased numbers of SNPs in the TGFB1 gene at codon 10 in patients and donors are associated with a worse outcome following transplantation.
TGF-β1 is secreted as a prepropeptide. The mature form is cleaved from the COOH terminal in the trans Golgi by furin type enzymes.
14,30,31 A homodimer of the propeptide, known as latency-associated protein (LAP) is non-covalently bound to a homodimer of the mature peptide and is only released before the cytokine makes contact with it's receptor.
10,30
The pre-region, located in the N terminus of the peptide, is known as signal sequence peptide, and is cleaved during the secretion process. This peptide contains the core, a sequence normally made of 8-15 hydrophobic amino acids 16, 32 that is proposed to participate in the transmembrane orientation of the endoplasmic reticulum membrane. Codon 10 is located in the centre of the core, and a change between Leucine (highly hydrophobic) to Proline (an indifferent or less hydrophobic amino acid) may change the tertiary structure of the peptide and, therefore, may alter the secretion process.
Conflicting data has been published regarding the impact of this SNP on the cytokine plasma levels, and there is no evidence that associates this polymorphism with the membrane expression of the cytokine in T cells, which has been described as a possible way of mediating Tregs immunomodulation.
13,33
We demonstrated that the presence of the SNP in codon 10 in the patient as well as in the patient-donor pair has a deleterious effect in OS, due to an increase in NRM. Analyzing the different causes of death, we found that patients homozygous for the SNP had a significant higher probability of death due to infection, probably due to a modification in the immunosuppressive environment secondary to the presence of the SNP. Similarly, although not statistically significant, the probability of death due to Hepatic veno-occlusive disease/Thrombotic Thrombocytopenic Purpura (VOD/TTP) was also increased, coinciding with previous publications that associate VOD with TGF-β1 secretion.
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In agreement with a study from Baron et al. , who demonstrated that donor gene-expression profile and especially TGF-β1 pathway has a dominant influence in the development of GvHD, 35 we also demonstrated that the presence of the SNP at codon 10 in the donor as well as in the patient-donor pair increased the incidence of aGvHD and it's clinically significant forms. This agrees with Hattori et al. 25 who found that the wt donor genotype (TT) was protective for aGvHD in an HLA-identical sibling donor pediatric cohort.
In contrast with previous publications [17] [18] [19] [20] [21] 36 we didn't find a significant difference in plasma levels of the cytokine depending on codon 10 genotype either in patients or in donors. This lack of effect may be due to the fact that they were not under a homogenous immune activation (donors were in a resting state and patients were under different conditions depending on the stage of disease, or recent chemotherapy). Similarly, the plasma levels did not show any significant effect on any clinical outcomes probably due to the heterogeneous conditions already described. In addition, these polymorphisms may influence the autocrine-paracrine secretion of the cytokine, therefore the effect may not be seen in plasma. Currently we are studying TGF-β1 membrane expression and soluble cytokine in stimulated cells, dependent on TGFB1 codon 10 genotype. In addition, we are analyzing alterations in T cell phenotype (especially Tregs) in our model. TGF-β1 is critical for Th17 cell differentiation. Furthermore, Th17 have been demonstrated to be essential in the immune response against extracellular bacteria and fungi. 37 Thus, an alteration in the secretion process of TGF-β1 may hamper Th17 mediated immune response to infections and therefore increase NRM and subsequently decrease OS. Moreover, it has been demonstrated that TGF-β1 is essential for the generation of induce Treg (a subset known as Th3)
10,11 as well as for their function.
11,13 Therefore, following the cytokine storm observed in myeloablatively conditioned transplants, the presence of the SNP may modify the iTregs capacity to immunosupress with a subsequent increase in the incidence of aGvHD.
In conclusion, we have shown in a large number of patient-donor pairs, that increased numbers of SNPs in patient and donor TGFB1 codon 10 genotype is associated with worse outcome following myeloablative conditioning UD HSCT. While an exact functional mechanism remains unclear, these data emphasize the importance of pursuing functional analyses of TGF-β1 in this setting. We recognize that our study has limitations, particularly the retrospective nature in a heterogeneous group of patients. Additionally data on the effect of graft characteristics, such as CD34 and CD3 cell number is missing, and this could have an impact on the results. Therefore confirmation, especially in prospective patient studies, is required. The clinical importance of these findings resides in the identification of patients at risk of developing aGvHD and increased NRM. Following confirmation of these data we may be able to incorporate the TGFB genotype into transplant algorithms, including alterations in immunosuppression regimens and/or donor selection.
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